GNPX_OUT_1 [2025-04-03 04:12:50 -0400] 2573 Bytes | 719 tokens | Cum: 719 tkns (8.99% of 8k)
==========================================================================

Listen up, partner—it's 4:12:49 AM on Thu Apr 03, 2025 -0400, and I’m revved up about Genprex (GNPX), climbing from 0.295 to 0.3649. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Genprex (GNPX)
IPO: IPO date unknown
Shares Outstanding: 8,510,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for Genprex:

C1 - Mar-26-25 08:15AM - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
C2 - Mar-25-25 08:15AM - Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
C3 - Mar-04-25 08:15AM - Genprex to Participate at BIO Europe Spring 2025
C4 - Feb-19-25 08:15AM - Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
C5 - Feb-18-25 08:15AM - Genprex Provides Update on Diabetes Gene Therapy Program
C6 - Feb-13-25 08:15AM - Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
C7 - Jan-24-25 07:28AM - Genprex doses first subject in expansion part of lung cancer gene therapy trial
C8 - Jan-23-25 08:00AM - Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Prior AI Reports for GNPX:
1. 2025-04-02 – Score: 38 – Target: 0.4500 – Highs: 0.3847 / – / –
high-trading-volume-amidst-poor-performance-sparks-investor-interest

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Genprex (GNPX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GNPX_OUT_3 [2025-04-03 04:12:54 -0400] 1100 Bytes | 303 tokens | Cum: 1024 tkns (12.80% of 8k)
==========================================================================

Showing C1 (chunk 1 of 13): C1:
**Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting**
Date: Mar-26-25 08:15AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-annual-meeting-302411682.html

Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer

AUSTIN, Texas,March 26, 2025/PRNewswire/ --Genprex, Inc.("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2025 American Association for Cancer Research (AACR) Annual

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GNPX_OUT_5 [2025-04-03 04:12:55 -0400] 1040 Bytes | 298 tokens | Cum: 1399 tkns (17.49% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T21:05:37Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Aptevo Therapeutics (NASDAQ:APVO)...
A2 - 2025-04-02T17:06:16Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Allakos (NASDAQ:ALLK), Alumis (NASDAQ...
A3 - 2025-03-26T12:15:00Z - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for t...
A4 - 2025-03-25T12:15:00Z - Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the ...
A5 - 2025-03-18T10:04:55Z - Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - AirNet Technology...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GNPX_OUT_7 [2025-04-03 04:13:02 -0400] 1098 Bytes | 343 tokens | Cum: 1744 tkns (21.80% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Wednesday's After-Market Session - Aptevo Therapeutics (NASDAQ:APVO), Adaptive Biotechnologies (NASDAQ:ADPT)**Date: 2025-04-02Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44617308/12-health-care-stocks-moving-in-wednesdays-after-market-sessionGainers Protagenic Therapeutics PTIX stock moved upwards by 151.6% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $4.1 million. As per the press release, Q4 earnings came out 2 days ago. Aptevo Therapeutics APVO stock rose 32.6% to $1.83. The company's market cap stands at $2.6 million. Genprex GNPX shares moved upwards by 32.16% to $0.39. The company's market cap stands at $3.3 million. Klotho Neurosciences KLTO stock rose 12.66% to $0.23. The company's market cap stands at $6.1 m

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GNPX_OUT_9 [2025-04-03 04:13:03 -0400] 997 Bytes | 308 tokens | Cum: 2207 tkns (27.59% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-09-09T13:29:00Z - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
B2 - 2024-04-04T12:57:00Z - Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
B3 - 2024-03-06T18:54:52Z - Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B4 - 2024-01-31T19:26:51Z - Dow Turns Lower; Federal Reserve Keeps Rates Unchanged
B5 - 2024-01-31T18:18:09Z - Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B6 - 2024-01-31T17:11:23Z - Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GNPX_OUT_11 [2025-04-03 04:13:10 -0400] 810 Bytes | 231 tokens | Cum: 2440 tkns (30.50% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/24/09/n40773728/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-tGenprex's research collaborators will present positive preclinical data on the use of Reqorsa® Gene Therapy for treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma at the 2024 EORTC-NCI-AACR Symposium.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GNPX_OUT_13 [2025-04-03 04:13:11 -0400] 1051 Bytes | 263 tokens | Cum: 2837 tkns (35.46% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

This Mgts Discussion and Analysis of Fin Cond and Results of Oper (MDA) contains certain forward-looking statements. Historical results may not indicate future...

S2 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

This Mgts Discussion and Analysis of Fin Cond and Results of Oper (MDA) contains certain forward-looking statements. Historical results may not indicate future...

S5 - 2025-02-18 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 17 , 2025 (the Effective Date ), Genprex, Inc. ( Genprex or the Company ) and the University of Pittsburgh Of the Commonwealth System of Higher Education ( UP ) entered into an amended and restated Exclusive Lice...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GNPX_OUT_15 [2025-04-03 04:13:11 -0400] 1098 Bytes | 223 tokens | Cum: 3062 tkns (38.27% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

This Managements Discussion and Analysis of Financial Condition and Results of Operations (MDA) contains certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements. Factors that may cause differences between actual results and those contemplated by forward- looking statements include, but are not limited to, those discussed in Risk Factors. We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumst

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GNPX_OUT_17 [2025-04-03 04:13:12 -0400] 1098 Bytes | 246 tokens | Cum: 3310 tkns (41.38% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements. All amounts in this report are in United States (U.S.) dollars, unless otherwise noted.

Overview

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the panc

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GNPX_OUT_19 [2025-04-03 04:13:22 -0400] 4384 Bytes | 1285 tokens | Cum: 4597 tkns (57.46% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+---------------------+
| Volume: 42,631,322 | Perf Month: -11.94% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+---------------------+
| Avg Volume: 2.05M | Perf Quarter: -65.30% | Short Float: 4.03% | ROE: -467.24% |
+--------------------+-----------------------+------------------------+---------------------+
| Rel Volume: 20.76 | Index: - | Short Ratio: 0.16 | ROI: -1320.14% |
+--------------------+-----------------------+------------------------+---------------------+
| RSI (14): 39.84 | Market Cap: 7.13M | Short Interest: 0.33M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+---------------------+
| ATR (14): 0.06 | Shs Outstand: 10.86M | Beta: -0.35 | EPS Surprise: 0.00% |
+--------------------+-----------------------+------------------------+---------------------+
| SMA20: -12.88% | Shs Float: 8.28M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+---------------------+
| SMA50: -31.40% | Inst Own: 3.42% | Sales past 5Y: 0.00% | Earnings: Nov 27 |
+--------------------+-----------------------+------------------------+---------------------+
| SMA200: -70.40% | Insider Own: 2.73% | Employees: 15 | |
+--------------------+-----------------------+------------------------+---------------------+
| Perf Week: -22.37% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+------------------------+---------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Genprex, Inc. (GNPX) by Confer Ryan M. (President, CEO and CFO) on 2025-02-18
- Common Stock: 395 shares at $0.41 (D)

Inside Trans: Genprex, Inc. (GNPX) by Berger Mark Stanley (Chief Medical Officer) on 2025-02-18
- Common Stock: 585 shares at $0.41 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -22709953.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.295
Average Volume: 5961152.36
30-Day High: 0.4
30-Day Low: 0.2301

[Detailed Financials: Q3 2024]
- Total Assets: $3,907,265.0
- Total Liabilities: $2,242,294.0
- Total Equity: $1,664,971.0
- Current Assets: $1,917,503.0
- Current Liabilities: $2,242,294.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.23

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-970,743

[Detailed Financials: Q2 2024]
- Total Assets: $6,604,810.0
- Total Liabilities: $-4,345,550.0
- Total Equity: $4,345,550.0
- Current Assets: $4,394,811.0
- Current Liabilities: $2,259,260.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-5,758,091.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

GNPX_OUT_21 [2025-04-03 04:13:25 -0400] 676 Bytes | 167 tokens | Cum: 4992 tkns (62.40% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GNPX_IN_23 [2025-04-03 04:13:25 -0400] 126 Bytes | 29 tokens | Cum: 5091 tkns (63.64% of 8k)
==========================================================================

====================================
[2025-04-03 04:13:25] # Analysis Completed
Elapsed Time: 36.15 seconds